Targeted gene therapy for breast cancer with truncated Bid.

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• The proapoptotic factor tBid can induce cancer cell death.
• Targeting gene therapy to tumor cells requires specific promoters.
• Tumor-specific promoters like hTERT, Survivin, and Muc1 are potential candidates for targeted gene delivery.

Purpose of the Study:

• To evaluate the efficiency of tBid delivered via tumor-specific promoters (hTERT, Survivin, Muc1) in killing breast cancer cells.
• To determine if gene expression levels of hTERT, Survivin, and Muc1 can predict the activity of their respective promoters.
• To assess the correlation between promoter activity and breast cancer cell killing.

Main Methods:

• Utilized breast cancer cell lines with varying expression levels of hTERT, Survivin, and Muc1.
• Cloned the proapoptotic factor tBid under the control of CMV, hTERT, Survivin, and Muc1 promoters.
• Assessed promoter activity and correlated it with gene expression and tumor cell killing efficacy.

Main Results:

• tBid expression under a strong CMV promoter was highly effective in killing breast cancer cells.
• Tumor-specific promoters showed significant tumor cell killing in cell lines with high promoter activity.
• Muc1 gene expression correlated well with its promoter activity and cell killing.
• hTERT and Survivin promoter activity did not correlate well with their respective gene expression levels.

Conclusions:

• Targeted delivery of tBid using tumor-specific promoters is a viable strategy for breast cancer gene therapy.
• Muc1 shows potential as a reliable marker for predicting promoter activity and therapeutic outcome.
• Discrepancies in hTERT and Survivin gene expression versus promoter activity warrant further investigation for optimizing gene therapy constructs.